- Home
- ALLK vs ENTX Comparison
ALLK vs ENTX Comparison
Compare ALLK & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLK
- ENTX
- Stock Information
- Founded
- ALLK 2012
- ENTX 2010
- Country
- ALLK United States
- ENTX Israel
- Employees
- ALLK N/A
- ENTX N/A
- Industry
- ALLK Biotechnology: Pharmaceutical Preparations
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALLK Health Care
- ENTX Health Care
- Exchange
- ALLK Nasdaq
- ENTX Nasdaq
- Market Cap
- ALLK 58.0M
- ENTX 67.2M
- IPO Year
- ALLK 2018
- ENTX 2018
- Fundamental
- Price
- ALLK $1.16
- ENTX $1.73
- Analyst Decision
- ALLK Hold
- ENTX Strong Buy
- Analyst Count
- ALLK 5
- ENTX 1
- Target Price
- ALLK $1.67
- ENTX $10.00
- AVG Volume (30 Days)
- ALLK 1.3M
- ENTX 127.7K
- Earning Date
- ALLK 11-06-2024
- ENTX 11-08-2024
- Dividend Yield
- ALLK N/A
- ENTX N/A
- EPS Growth
- ALLK N/A
- ENTX N/A
- EPS
- ALLK N/A
- ENTX N/A
- Revenue
- ALLK N/A
- ENTX $99,000.00
- Revenue This Year
- ALLK N/A
- ENTX N/A
- Revenue Next Year
- ALLK N/A
- ENTX N/A
- P/E Ratio
- ALLK N/A
- ENTX N/A
- Revenue Growth
- ALLK N/A
- ENTX 607.14
- 52 Week Low
- ALLK $0.54
- ENTX $0.52
- 52 Week High
- ALLK $3.41
- ENTX $3.35
- Technical
- Relative Strength Index (RSI)
- ALLK 51.18
- ENTX 44.32
- Support Level
- ALLK $1.29
- ENTX $1.64
- Resistance Level
- ALLK $1.56
- ENTX $1.80
- Average True Range (ATR)
- ALLK 0.14
- ENTX 0.09
- MACD
- ALLK -0.03
- ENTX -0.01
- Stochastic Oscillator
- ALLK 14.89
- ENTX 30.00
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.